company background image

DiaMedica Therapeutics NasdaqCM:DMAC Stock Report

Last Price


Market Cap







04 Oct, 2022


Company Financials +
DMAC fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health6/6

DMAC Stock Overview

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases.

DiaMedica Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for DiaMedica Therapeutics
Historical stock prices
Current Share PriceUS$1.21
52 Week HighUS$4.80
52 Week LowUS$1.15
1 Month Change-31.25%
3 Month Change-40.10%
1 Year Change-69.29%
3 Year Change-36.65%
5 Year Change-81.33%
Change since IPO-96.38%

Recent News & Updates

Jul 06

FDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical hold

DiaMedica Therapeutics (NASDAQ:DMAC) on Wednesday said the U.S. FDA had placed a clinical hold on its phase 2/3 trial evaluating its product candidate DM199 for the treatment of a type of stroke called acute ischemic stroke. The trial, called ReMEDy2, was put on hold as three serious cases of low blood pressure in stroke patients were reported after they received an injection of DM199. The company said it had paused patient enrollment, and believes the low blood pressure events were due to the use of a different intravenous bag in the ReMEDy2 trial from the one used in the prior ReMEDy1 trial. "...the company is confirming the differences in drug absorption in the IV bags used in the ReMEDy1 trial compared to the ReMEDy2 trial and plans to work with the FDA to modify the ReMEDy2 trial protocol to adjust the DM199 IV dosing to more closely match the dosing in the ReMEDy1 trial, taking into account these differences", DMAC said. DMAC said that no such low blood pressure issues were reported in the ReMEDy1 trial.

Jun 16
We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate

We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

DMACUS BiotechsUS Market

Return vs Industry: DMAC underperformed the US Biotechs industry which returned -22.7% over the past year.

Return vs Market: DMAC underperformed the US Market which returned -20% over the past year.

Price Volatility

Is DMAC's price volatile compared to industry and market?
DMAC volatility
DMAC Average Weekly Movement16.1%
Biotechs Industry Average Movement11.1%
Market Average Movement6.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: DMAC is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: DMAC's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

200015Rick Pauls

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company’s lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases.

DiaMedica Therapeutics Fundamentals Summary

How do DiaMedica Therapeutics's earnings and revenue compare to its market cap?
DMAC fundamental statistics
Market CapUS$32.79m
Earnings (TTM)-US$13.56m
Revenue (TTM)n/a


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DMAC income statement (TTM)
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$13.56m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-0.51
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did DMAC perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is DMAC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 1/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DMAC?

Other financial metrics that can be useful for relative valuation.

DMAC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does DMAC's PB Ratio compare to its peers?

DMAC PB Ratio vs Peers
The above table shows the PB ratio for DMAC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average0.8x
CYCC Cyclacel Pharmaceuticals
ASLN ASLAN Pharmaceuticals
AIKI AIkido Pharma
IDRA Idera Pharmaceuticals
DMAC DiaMedica Therapeutics

Price-To-Book vs Peers: DMAC is expensive based on its Price-To-Book Ratio (0.8x) compared to the peer average (0.8x).

Price to Earnings Ratio vs Industry

How does DMAC's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: DMAC is good value based on its Price-To-Book Ratio (0.8x) compared to the US Biotechs industry average (1.7x)

Price to Book Ratio vs Fair Ratio

What is DMAC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DMAC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate DMAC's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of DMAC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate DMAC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate DMAC's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Future Growth

How is DiaMedica Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: DMAC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: DMAC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: DMAC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: DMAC is forecast to have no revenue next year.

High Growth Revenue: DMAC is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if DMAC's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has DiaMedica Therapeutics performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: DMAC is currently unprofitable.

Growing Profit Margin: DMAC is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: DMAC is unprofitable, and losses have increased over the past 5 years at a rate of 26.7% per year.

Accelerating Growth: Unable to compare DMAC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DMAC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).

Return on Equity

High ROE: DMAC has a negative Return on Equity (-35.96%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is DiaMedica Therapeutics's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: DMAC's short term assets ($39.2M) exceed its short term liabilities ($1.5M).

Long Term Liabilities: DMAC's short term assets ($39.2M) exceed its long term liabilities ($7.0K).

Debt to Equity History and Analysis

Debt Level: DMAC is debt free.

Reducing Debt: DMAC had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DMAC has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: DMAC has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 25.2% each year

Discover healthy companies


What is DiaMedica Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

DiaMedica Therapeutics Dividend Yield vs Market
How does DiaMedica Therapeutics dividend yield compare to the market?
SegmentDividend Yield
Company (DiaMedica Therapeutics)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.6%
Industry Average (Biotechs)2.8%
Analyst forecast in 3 Years (DiaMedica Therapeutics)n/a

Notable Dividend: Unable to evaluate DMAC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DMAC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DMAC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DMAC's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as DMAC has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Rick Pauls (51 yo)





Mr. Dietrich John Pauls, also known as Rick, MBA has been Chief Executive Officer and President of DiaMedica Therapeutics Inc. since January 2010 and has been its Director since April 2005. Mr. Pauls was a...

CEO Compensation Analysis

Rick Pauls's Compensation vs DiaMedica Therapeutics Earnings
How has Rick Pauls's remuneration changed compared to DiaMedica Therapeutics's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a


Mar 31 2022n/an/a


Dec 31 2021US$1mUS$477k


Sep 30 2021n/an/a


Jun 30 2021n/an/a


Mar 31 2021n/an/a


Dec 31 2020US$878kUS$455k


Sep 30 2020n/an/a


Jun 30 2020n/an/a


Mar 31 2020n/an/a


Dec 31 2019US$2mUS$420k


Sep 30 2019n/an/a


Jun 30 2019n/an/a


Mar 31 2019n/an/a


Dec 31 2018US$734kUS$315k


Sep 30 2018n/an/a


Jun 30 2018n/an/a


Mar 31 2018n/an/a


Dec 31 2017US$502kUS$280k


Sep 30 2017n/an/a


Jun 30 2017n/an/a


Mar 31 2017n/an/a


Dec 31 2016US$388kUS$276k


Sep 30 2016n/an/a


Jun 30 2016n/an/a


Mar 31 2016n/an/a


Dec 31 2015US$289kUS$180k


Compensation vs Market: Rick's total compensation ($USD1.14M) is above average for companies of similar size in the US market ($USD772.75K).

Compensation vs Earnings: Rick's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: DMAC's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Experienced Board: DMAC's board of directors are considered experienced (3.4 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: DMAC insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

NasdaqCM:DMAC Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
08 Jul 22BuyUS$275,898Thomas von KochIndividual207,974US$1.33
08 Jul 22BuyUS$400,197Thomas von KochIndividual304,827US$1.36

Ownership Breakdown

What is the ownership structure of DMAC?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders9,033,68934.2%
General Public14,548,30655.0%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 40.8%.

Top Shareholders

Top 25 shareholders own 44.84% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
Thomas von Koch
2,855,847$3.5m11.95%no data
Jan Stahlberg
2,551,020$3.1m0%no data
Richard Jacinto
1,649,053$2.0m0%no data
Laurence Lytton
1,380,266$1.7m0%no data
Stonepine Capital Management LLC
The Vanguard Group, Inc.
782,640$947.0k0%no data
Jacob Asset Management of New York LLC
Timothy Lynch
200,259$242.3k0%no data
R. Giuffre
177,079$214.3k0%no data
Geode Capital Management, LLC
177,022$214.2k1.24%no data
Northern Trust Global Investments
101,704$123.1k1.76%no data
Richard Pilnik
68,090$82.4k0%no data
BlackRock, Inc.
66,717$80.7k18.21%no data
State Street Global Advisors, Inc.
66,629$80.6k0%no data
Dimensional Fund Advisors LP
58,015$70.2k0%no data
Morgan Stanley, Investment Banking and Brokerage Investments
47,800$57.8k43.02%no data
Amy Burroughs
44,950$54.4k0%no data
Harry Alcorn
43,981$53.2k0%no data
BNY Mellon Asset Management
36,248$43.9k-0.45%no data
Dietrich Pauls
35,804$43.3k5.14%no data
Two Sigma Advisers, LP
26,700$32.3k-45.95%no data
Scott Kellen
22,290$27.0k0%no data
Citadel Advisors LLC
18,012$21.8k-52.89%no data
Two Sigma Investments, LP
17,249$20.9k-65.55%no data
Cantor Fitzgerald Asset Management
14,691$17.8k0%no data

Company Information

DiaMedica Therapeutics Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: DiaMedica Therapeutics Inc.
  • Ticker: DMAC
  • Exchange: NasdaqCM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$32.789m
  • Shares outstanding: 26.44m
  • Website:

Number of Employees


  • DiaMedica Therapeutics Inc.
  • Two Carlson Parkway
  • Suite 260
  • Minneapolis
  • Minnesota
  • 55447
  • United States


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DMACNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDMar 2007
F2KADB (Deutsche Boerse AG)YesCommon SharesDEEURMar 2007

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/04 00:00
End of Day Share Price2022/10/04 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.